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2 of 27 patients with genital involvement (81%), 11 of 16 patients
ith whitlow ulcers (69%), and in 5 of 23 patients with other body
arts ulcers (22%).
Conclusion: Taking into account the high sensitivity, repro-
ucibility and speciﬁcity, the real-time PCR assay can be used for
he rapid detection of HSV DNA from skin origin clinical samples,
specially in difﬁcult clinical cases.
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Background: Bacterial resistance due to beta-lactamases and
other mechanisms has continued to increase over the past sev-
eral years, particularly in Asia/Paciﬁc; however, tigecycline has
thus far retained a broad spectrum of activity against many of the
species which have become largely resistant to other antimicro-
bics. The Tigecycline Evaluation Surveillance Trial (TEST) program
is an ongoing global surveillance study which has tracked in vitro
activity of several drugs since 2004. This report from TEST sum-
marizes the susceptibility of aerobic pathogens of intra-abdominal
infections (IAI) in Asia/Paciﬁc from 2004-2011.
Methods: 975 aerobic isolates from IAI sources were collected
from 12 Asia/Paciﬁc countries from 2004-2011. Isolates were iden-
tiﬁed to the species level at participating sites and conﬁrmed by a
central laboratory in the USA. Minimum Inhibitory Concentrations
(MICs) were determined at each site using supplied broth microdi-
lution panels and interpreted according to CLSI/FDA guidelines.
Results: Susceptibility percentages for species with n≥10 are
summarized below; values ≥90% are shaded:
igecycline’s MIC90 vs. A. baumannii and Acinetobacter spp. were
2 and 1 mcg/ml, respectively.
Conclusion: Tigecycline inhibited >90% of all tested species for
which breakpoints exist. Like all tetracycline derivatives, tigecy-
cline has poor activity vs. P. aeruginosa. Although there are no
breakpoints established for tigecycline and Acinetobacter spp., its
in vitro activity against these often multi-drug-resistant (MDR)
organisms is interesting given the diminishing treatment options
for infections caused by MDR A. baumannii. Tigecycline retains
excellent in vitro activity against most of the species causing these
infections.
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